Literature DB >> 9211064

Peroxisome proliferator-activated receptors, orphans with ligands and functions.

K Schoonjans1, G Martin, B Staels, J Auwerx.   

Abstract

The three peroxisome proliferator-activated receptors (PPARs), PPAR alpha, delta and gamma, form a subfamily of the nuclear hormone receptor gene family. PPAR alpha has been shown to bind and be activated by leukotriene B4 and fibrates, whereas prostaglandin J2 derivatives and the antidiabetic thiazolidinediones, respectively, are natural and synthetic ligands for PPAR gamma. The availability of ligands and activators for PPAR alpha and PPAR gamma allowed an initial assessment of their respective functions. PPAR alpha and PPAR gamma are shown to function as important regulators in lipid and glucose metabolism, adipocyte differentiation, inflammatory response and energy homeostasis. PPAR alpha seems to mediate its pleiotropic effects mainly through the stimulation of oxidation of lipids, whereas PPAR gamma is a key mediator of lipid storage. The next few years will be very exciting as additional studies will refine our current knowledge about PPAR alpha and PPAR gamma and may reveal a ligand and role for the lonesome orphan among the PPARs, PPAR delta.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9211064     DOI: 10.1097/00041433-199706000-00006

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  81 in total

1.  Prostaglandin and PPAR control of immune cell function.

Authors:  Dino Rotondo; Jillian Davidson
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

2.  Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort.

Authors:  A Schäffler; N Barth; G Schmitz; B Zietz; K D Palitzsch; J Schölmerich
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 3.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Obesity treatment by epigallocatechin-3-gallate-regulated bile acid signaling and its enriched Akkermansia muciniphila.

Authors:  Lili Sheng; Prasant Kumar Jena; Hui-Xin Liu; Ying Hu; Nidhi Nagar; Denise N Bronner; Matthew L Settles; Andreas J Bäumler; Yu-Jui Yvonne Wan
Journal:  FASEB J       Date:  2018-06-08       Impact factor: 5.191

5.  Germinated waxy black rice extract inhibits lipid accumulation with regulation of multiple gene expression in 3T3-L1 adipocytes.

Authors:  Won Chul Lim; Jin Nyoung Ho; Hee Seop Lee; Hong Yon Cho
Journal:  Food Sci Biotechnol       Date:  2016-06-30       Impact factor: 2.391

6.  Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.

Authors:  Charles Brouillette; Yohan Bossé; Louis Pérusse; Daniel Gaudet; Marie-Claude Vohl
Journal:  J Hum Genet       Date:  2004-07-13       Impact factor: 3.172

7.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

8.  The Role of PPARα Activation in Liver and Muscle.

Authors:  Lena Burri; G Hege Thoresen; Rolf K Berge
Journal:  PPAR Res       Date:  2010-08-18       Impact factor: 4.964

Review 9.  The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Authors:  Norman L Eberhardt; Stefan K G Grebe; Bryan McIver; Honey V Reddi
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

10.  Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

Authors:  Unni Syversen; Astrid K Stunes; Björn I Gustafsson; Karl J Obrant; Lars Nordsletten; Rolf Berge; Liv Thommesen; Janne E Reseland
Journal:  BMC Endocr Disord       Date:  2009-03-30       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.